Abstract Coronavirus disease 2019 (COVID-19) is especially severe in aged populations.
Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are …

Abstract The coronavirus disease 2019 (COVID-19) was declared a pandemic in March
2020 by the World Health Organization (WHO). To date, there were> 163 million confirmed …

BACKGROUND COVID-19 convalescent plasma (CCP) has been considered a treatment
option for COVID-19. This trial assessed the efficacy of a neutralizing antibody containing …

In patients with severe COVID‐19, acute respiratory distress syndrome (ARDS), multiple
organ dysfunction syndrome (MODS), and even mortality can result from cytokine storm …

Background Illness after infection with the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) Omicron variant is less severe compared with previous variants. Data on the …

Background Many patients with COVID-19 have been treated with plasma containing anti-
SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent …

Identification of high‐risk patients admitted to intensive care with COVID‐19 may inform
management strategies. The objective of this meta‐analysis was to determine factors …

The immune system is the central regulator of tissue homeostasis, ensuring tissue
regeneration and protection against both pathogens and the neoformation of cancer cells. Its …

Background Tixagevimab–cilgavimab is a neutralising monoclonal antibody combination
hypothesised to improve outcomes for patients hospitalised with COVID-19. We aimed to …

Background Patients with severe COVID-19 have emerged as a population at high risk of
invasive fungal infections (IFIs). However, to our knowledge, the prevalence of IFIs has not …